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Abstract
Background: The use of lipid emulsions has been associated with changes in lung function and gas exchange
which may be mediated by biologically active metabolites derived from arachidonic acid. The type and quantity of
the lipid emulsions used could modulate this response, which is mediated by the eicosanoids. This study
investigates the use of omega-3 fatty acid-enriched lipid emulsions in ARDS patients and their effects on
eicosanoid values.
Methods: Prospective, randomized, double-blind, parallel group study carried out at the Intensive Medicine
Department of Vall d’Hebron University Hospital (Barcelona-Spain). We studied 16 consecutive patients with ARDS
and intolerance to enteral nutrition (14 men; age: 58 ± 13 years; APACHE II score 17.8 ± 2.3; Lung Injury Score:
3.1 ± 0.5; baseline PaO2/FiO2 ratio: 149 ± 40). Patients were randomized into two groups: Group A (n = 8) received
the study emulsion Lipoplus
® 20%, B. Braun Medical (50% MCT, 40% LCT, 10% fish oil (FO)); Group B (n = 8)
received the control emulsion Intralipid
® Fresenius Kabi (100% LCT). Lipid emulsions were administered for 12 h at
a dose of 0.12 g/kg/h. We measured LTB4, TXB2, and 6-keto prostaglandin F1a values at baseline [immediately
before the administration of the lipid emulsions (T-0)], at the end of the administration (T-12) and 24 hours after
the beginning of the infusion (T 24) in arterial and mixed venous blood samples.
Results: In group A (FO) LTB4, TXB2, 6-keto prostaglandin F1a levels fell during omega-3 administration (T12). After
discontinuation (T24), levels of inflammatory markers (both systemic and pulmonary) behaved erratically. In group B
(LCT) all systemic and pulmonary mediators increased during lipid administration and returned to baseline levels
after discontinuation, but the differences did not reach statistical significance. There was a clear interaction
between the treatment in group A (fish oil) and changes in LTB4 over time.
Conclusions: Infusion of lipids enriched with omega-3 fatty acids produces significant short- term changes in
eicosanoid values, which may be accompanied by an immunomodulatory effect.
Trial registration: ISRCTN63673813.
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The lipid emulsions administered in parenteral nutrition
(PN) of critically ill patients are rich in long chain trigly-
cerides (LCT), particularly linoleic acid (18:2 n-6), so as
to ensure optimum energy intake and to prevent essen-
tial fatty acid deficiency [1]. However, in addition to
their adverse metabolic effects, these fatty acids may
alter pulmonary gas exchange due to their potential
pro-inflammatory properties, particularly in high risk
patients such as those with respiratory failure [2-5].
ARDS is a clinical condition characterized by acute
severe respiratory failure, with an estimated incidence of
200,000 cases/year in the US. Despite recent advances in
overall support, ARDS still presents high comorbidity
and mortality rates of over 40% [6-8].
A large number of factors that might be involved in
the genesis of ARDS have been identified, such as sev-
eral vasoactive substances which promote cell aggrega-
tion and modify permeability. Histamine, serotonin, the
cytokine system, and some lipid mediators (prostaglan-
dins, leukotrienes and platelet activating factor - PAF)
are some of these factors.
Linoleic acid is the precursor of arachidonic acid and
therefore indirectly the precursor of the arachidonic
acid-derived lipid mediators known as eicosanoids [9].
Some eicosanoids are inflammatory mediators with high
biological activity and are associated with a large num-
ber of disease processes, both acute (ARDS, acute pan-
creatitis, etc.), and chronic (asthma, rheumatoid
arthritis, Crohn’s disease, etc.) [10-13].
Several strategies have been designed to minimize
linoleic acid intake and its possible adverse effects,
among them the administration of emulsions with mix-
tures of long-chain and medium-chain fatty acids (LCT-
MCT), or of emulsions enriched with olive oil or with
n-3 fatty acids (FO). This latter option is potentially the
most interesting; although the administration of FO via
the enteral route has been widely studied, the parenteral
route in patients with ARDS has not been explored in
depth [5,14-17].
Whereas linoleic acid synthesizes series-2 and series-4
eicosanoids via the arachidonic pathway, the n-3 fatty
acids synthesize the series-3 eicosanoids, which have a
much lower biologically active profile than mediators
derived from linoleic acid [18].
Many patients with ARDS have digestive intolerance.
We believe that ARDS patients who tolerate parenteral
nutrition might benefit from a lipid emulsion enriched
with FO administered as lipid intake.
The present study explores whether parenteral admin-
istration of a lipid emulsion with a lower amount of
linoleic acid and enriched with FO fatty acids can mod-
ulate the synthesis of biologically active eicosanoids in
patients with ARDS.
Methods
We studied 16 consecutive patients with ARDS in the
first 48 hours after admission, enrolled after approval
of the clinical trial by the Vall d’Hebron University
Hospital Clinical Trials Committee. The inclusion criteria
were: sudden onset of bilateral pulmonary infiltrates in
the chest x-ray; PaO2/FiO2 ratio ≤ 200; pulmonary capil-
lary pressure ≤ 18 mm Hg [6] and requirement of PN
according to the recommendations of the American
Society of Parenteral and Enteral Nutrition [19].
Exclusion criteria were: age < 18 or > 85 years, preg-
nancy, liver failure, HIV+, leukopenia (<3500 mm
3),
thrombocytopenia (<100000 mm
3), severe renal failure
(creatinine >6 mg/dl) or requirement of renal dialysis, his-
tory of organ transplant, multiple transfusions, participa-
tion in other clinical studies simultaneously or in the last
60 days, nitric oxide treatment, corticoids (prednisolone
dose greater than 2 mg/kg/d or equivalent), multi-organ
failure, severe dyslipemia or treatment with propofol.
The patients were sedated with morphine, midazolam
and muscle relaxants if required. All patients were
mechanically ventilated (7200 series Mallinckrodt Puri-
tan Bennett, Carlsbad, Calif., USA) in control mode.
They were monitored with continuous electrocardiogra-
phy, heart rate, arterial oxygen saturation using pulse
oximetry, invasive arterial pressure and a pulmonary
artery catheter with continuous cardiac output by
thermodilution.
Determination of eicosanoids
We studied the thromboxane B2 (TXB2) cyclooxygenase
pathway, a stable metabolite of TXA2, and 6-keto pros-
taglandin F1(6-keto PGF1a) a stable metabolite of pros-
tacyclin. We also studied leukotriene B4 (LTB4)o ft h e
lipoxygenase pathway.
The eicosanoids were analyzed in arterial blood (post-
pulmonary), by arterial access (femoral or radial) and in
mixed venous blood (pre-pulmonary) by means of a
Swan-Ganz catheter, by enzyme immunoassay (EIA);
Amersham International (Buckinghamshire, UK).
The reference values measured in the same laboratory
in healthy individuals were used as the normal range.
Study Design
The patients were randomly assigned to different groups
within the first 48 hours of ARDS diagnosis and before
receiving artificial nutrition. Group A patients (n = 8,
emulsion study group) received Lipoplus
® 20% B. Braun
Medical (50% MCT, 40% LCT, 10% FO). Group B (n =
8, control group) received Intralipid
® 20% Fresenius
Kabi (100% LCT). The lipid emulsions were adminis-
tered for 12 hours at 0.12 g/kg/h.
We measured concentrations of eicosanoids (TXB2,6 -
ketoPGF1a and LTB4) in the arterial and mixed venous
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tion of the lipid emulsions (T-0)], at the end of the
administration (T-12), and 24 hours from the start of
the infusion (T-24).
Statistical analysis
T h ed a t aw e r ei m p o r t e df r o mA c c e s sd a t a b a s e st oS P S S .
Means and standard deviations were calculated for numer-
ical variables. Differences in the means were analyzed by
the T-test. Differences in time of the parameters studied,
depending on the type of emulsion, were assessed by the
Wilcoxon test. We also studied the interaction between
treatment and all the eicosanoids using ANOVA. The
level of statistical significance was defined as p < 0.05.
Results
Characteristics of the studied population
The baseline characteristics are shown in Table 1. No
statistically significant differences were seen in the base-
line values.
Systemic eicosanoid values
Eicosanoid arterial blood values are shown in Table 2. All
the values measured in patients with ARDS during the
study, both in the arterial and mixed venous samples,
were higher than the reference values of the healthy
population. We observed significant differences between
the three eicosanoid baseline levels, which were higher in
Group A (FO) than in Group B.
There were clear differences in the two populations
with regard to the behaviour of the eicosanoids. In
group A, treated with the FO-enriched emulsion (group
A), all eicosanoid values tended to decrease after the
administration T(12). Twelve hours after ending perfu-
sion T(24), TXB2 levels increased compared with T(12)
but were lower than baseline levels T(O), LTB4 levels
decreased persistently, recording lower levels than T
(12), as did 6-keto-PGF1alevels, although only LTB4
levels presented statistically significant differences.
The opposite trend was seen in the group treated with
LCT, in which all the eicosanoid values rose after the
administration of the emulsion. Twelve hours after end-
ing perfusion T(24) TXB2 decreased compared with T
(12) but its levels remained higher than baseline T(0);
LTB4 levels continued to increase, being higher than at
T(12): 6-keto-PGF1a decreased with respect to T(12) but
remained higher than at baseline T(0).
Eicosanoid values in mixed venous blood
Eicosanoid values in mixed venous blood were also higher
than the reference values in the healthy population. In
group A, baseline LTB4 levels were significantly higher.
Table 1 Clinical characteristics of patients
Diagnosis Sex Age PaO2/FiO2 LIS APACHEII PEEP Outcome
Group A: FO
1. Pneumonia M 74 98 4 18 7 D
2. Pneumonia M 48 166 2.3 17 8 D
3. Pneumonia M 64 133 3.6 18 12 D
4. Sepsis M 50 189 3 15 10 L
5. Smoke aspiration M 40 132 3 16 11 L
6. Bronchoaspiration M 72 84 2.6 21 8 D
7. Mediastinitis M 70 147 3.3 19 10 L
8. Bronchoaspiration M 36 183 2.5 15 7 L
Total Group A: 8 M 56 ± 15 141 ± 37 3 ± 0.5 17.4 ± 2.1 9.1 ± 1.9 4D/4L
Group B: LCT
1. Pancreatitis F 52 152 3 16 11 L
2. Bronchoaspiration M 57 198 4 21 15 L
3. Bronchoaspiration M 56 177 2.6 17 9 D
4. Status postpneumectomy M 63 60 4 19 10 L
5. Pneumonia M 71 181 3 18 10 L
6. Pneumonia M 43 186 3.3 14 8 L
7. Pneumonia M 53 153 3 19 10 D
8. Pneumonia F 81 157 3 22 9 L
Total Group B 6M/2F 59 ± 12 158 ± 43 3.2 ± 0.5 18.2 ± 2.6 10.3 ± 2.1 2D/6L
Total n:16 14M/2F 58 ± 13 149 ± 40 3.1 ± 0.5 17.8 ± 2.3 9.7 ± 2 6D/10L
LIS: Lung Injury Score. APACHEII: Acute Physiology and Chronic Health Evaluation. PEEP: Positive End Expiratory Pressure. M: male. F: female. D: dead. L: alive.
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shown in Table 3. We found changes parallel to those
found at peripheral arterial level at the end of lipid
emulsion administration T(12). Twelve hours after the
end of lipid emulsion administration T(24) in the FO
group, TXB2 continued to decrease with respect to T
(12), as did LTB4,6 - k e t o - P G F 1a levels increased with
regard to T(12) but remained below baseline T(0) levels.
In the LCT group at T(24), TXB2 decreased with respect
to T(12) and fell below baseline levels, LTB4 increased
with regard to T(12), 6-keto-PGF1a decreased with
respect to T(12) but remained above baseline; however
the differences were small and did not reach statistical
significance.
Applying the ANOVA test, we observed a clear inter-
action between the treatment in group A (fish oil) and
changes in LTB4 over time with p < 0.001 (systemic
LTB4) and p < 0.01 (mixed venous blood).
Discussion
All the ARDS patients in our series presented higher
baseline values of eicosanoids, in both systemic arterial
and mixed venous blood, than the healthy population.
On administering the lipid emulsions at 0.12 g/kg/h for
12 hours, patients who received the LCT-rich emulsion
presented increased values in all eicosanoids at the end
of the infusion compared with baseline. Twelve hours
after the end of the emulsion, TXB2 and 6-keto-PGF1a
levels decreased and LTB4 levels, both systemic and pul-
monary, continued to increase. As for the patients who
received FO enriched lipid emulsion, all eicosanoid
values tended to decrease at the end of administration, at
both systemic and pulmonary level. Twelve hours after
the end of the administration the behaviour of the media-
t o r sw a sm o r ee r r a t i c .T h eo n l ys tatistically significant
difference was found in the LTB4 values at systemic level.
We observed significant differences in baseline eicosa-
noid levels, which were higher in the FO group, espe-
cially in the arterial blood sample. It is difficult to
evaluate these baseline differences in a population which
was otherwise totally homogeneous, but we think that
they may be due to the major interindividual eicosanoid
variability observed in critically ill patients. This makes
it even more important to use a point by point calcula-
tion instead of ANOVA, because the further away from
time 0, the more the circumstances may modify the
result and invalidate the conclusions.
The erratic behaviour of the lipid mediator 12 hours
after the end of the lípid emulsions may be due to the
loss of beneficial effect of FO and the increase in the
detrimental effect of LCT over time.
In this trial we focused on the effect of lipid emulsion
on eicosanoid synthesis. Hemodynamic and gas
exchange variations were discussed in a previous study
in which we did not observe any significant variation in
gas exchange, pulmonary mechanical parameters, or in
systemic and arterial hemodynamics [20], in contrast to
another recent report with a similar lipid emulsion [21].
Besides its gas exchange function, the lung is involved
in both the synthesis and catabolism of several inflam-
matory mediators [22]. We know that it is mainly
responsible for eicosanoid synthesis of PGI2 and TXA2,
which are considered the most important derivatives of
arachidonic acid in the lung. TXA2 m a yi n c r e a s el u n g
Table 2 (Systemic arterial eicosanoid levels according to the emulsion type administered (values in pg/ml)):
Emulsion A (FO) Emulsion B (LCT)
Normal
Value
T(0):Pre infusion
(Basal)
T(12):Post
infusion
T(24): 24 h
from
start of
infusion
T(0):Pre
infusion
(Basal)
T(12):Post
infusion
T(24): 24 h
from
start of
infusion
TXB2 <150 362.3 ± 128.9
(**) 278.5 ± 46.2 291.5 ± 120.6 206.4 ± 66.7
(**) 470.6 ± 243.2 262.7 ± 97.9
LTB4 <75 569.3 ± 312.2
(*)
(**)
283.3 ± 145.3
(*) 210.9 ± 114.6 233.4 ± 147.9
(**) 365.1 ± 206.2 550 ± 488.2
6-keto-PGF1a <50 633.4 ± 218
(**) 598.1 ± 240 526.9 ± 209.3 412.8 ± 132.8
(**) 708 ± 239.2 493.4 ± 156
(*) Intragroup significant differences.
(**) Basal values significant differences between both groups.
Table 3 (Eicosanoid levels in mixed venous blood according to the emulsion type administered (values in pg/ml)):
Emulsion A (FO) Emulsion B (LCT)
T(0):Pre infusion
(Basal)
T(12):Post infusion T(24): 24 h from
start of infusion
T(0):Pre infusion
(Basal)
T(12):Post infusion T(24): 24 h from
start of infusion
TXB2 375.4 ± 146.3 305.4 ± 70.3 279.6 ± 127.1 283.3 ± 123.4 326.1 ± 132.4 231 ± 88.9
LTB4 433 ± 186.2
(**) 239.6 ± 130.8 234.4 ± 111.8 200.3 ± 160.7
(**) 260.6 ± 150.5 342.6 ± 230.4
6-keto-PGF1a 660.1 ± 298.9 529.7 ± 178.3 566.4 ± 224.8 509.5 ± 134.6 746.4 ± 532.4 525.5 ± 298.3
(**) Basal values significant differences between both groups.
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Page 4 of 7vascular resistance, whilst prostacyclin dilates the vascu-
lar bed. The LTB4 released by the alveolar macrophages
and neutrophils is heavily involved in the inflammatory
response and facilitates capillary extravasation [23]. Sev-
eral authors suggest that leukotrienes may play a crucial
role in the development of ARDS after the initial cell
injury [24]. Furthermore, the leukotrienes, and particu-
larly LTB4, play an important role in pulmonary leuko-
cyte chemotaxis which, in turn, could trigger the rest of
the inflammatory cascade [25,26]. In fact, increased con-
centrations of leukotrienes have been found in the
bronchoalveolar lavage and plasma in patients with lung
injury, as well in those at risk of developing one [27,28].
Several studies have associated systemic levels of LTB4
with the severity of the ARDS and the degree of hypoxe-
mia. It has also been reported that the higher the
plasma levels of LTB4, the higher the degree of hypoxe-
mia. Increased mortality has been observed in patients
with higher baseline levels of plasma LTB4 [26,29]. All
these data confirm that LTB4 is a proinflammatory
molecule with a fundamental role in the cascade that
leads to the genesis and evolution of respiratory distress,
as well as being an excellent prognostic marker [25,27].
Attempts have been made to modulate the inflamma-
tory response in ARDS using various strategies (corti-
coids, indomethacin, etc.) without much success in
humans [30,31]. One enormously attractive approach
would be to modulate the release of final eicosanoid
mediators by modifying the intake of their potential
initial precursors. PN rich in LCT, and in particular in
linoleic acid, is known for its potential effects on the
synthesis of proinflammatory mediators and secondarily,
a potential deterioration in lung function [32,33] - as we
saw in our study in our LCT patients, who presented
significant increases in all eicosanoid values. Several
strategies have been used to minimize the intake of lino-
leic acid and to avoid its negative effects. The use of
e m u l s i o n sw i t hL C T / M C Tw o u l dl e a dt ot h es y n t h e s i s
of lower amounts of eicosanoid, since the rapidly oxi-
dized MCT would not act as eicosanoid precursors.
Many studies in the literature report clinically divergent
results [14,17,34-36]. Of course, MCT intake may
induce ketosis, with the limitations that this presents in
patients with diabetes mellitus or in similar situations
[37]. Comparing patients with ARDS treated with LCT
vs. LCT/MCT emulsions, our group reported neutral
results in eicosanoid synthesis [38]. A lower amount of
PUFA n-6 is provided in LCT/MCT emulsions, but the
n-6/n-3 ratio is not changed, with the result that non-
recommendable values may theoretically persist. Enrich-
ing lipid emulsions with FO, which could “modulate”
the response of the body to aggression, has been studied
as a treatment strategy in patients with ARDS receiving
enteral nutrition [16], but there is little information
available on patients with intolerance of the digestive
route and who require PN.
The use of OF-enriched PN has been shown to be safe
and well tolerated in critical patients [20,39]. There are
also many examples of a favourable profile in eicosanoid
synthesis, particularly of LTB4, in many chronic diseases
such as psoriasis [40]. But where it has been studied
most is in the surgical patient. In one series of surgical
patients the use of an emulsion consisting of LCT-
MCT-FO and olive oil minimized the production of
LTB4 and increased LTB5, and reduced hospital stay
[41]. An immunomodulatory effect on the generation of
lipid mediators has also been found after administering
an FO-enriched emulsion [42]. This same favourable
immunomodulatory effect could be observed in septic
patients [43].
Focusing on the effect of FO-enriched lipid emulsions
on acute lung injury (ALI) and ARDS, we found many stu-
dies of animal models but very few of humans. A protec-
tive effect of n-3 has been reported in ALI animal models;
the administration of arachidonic acid (AA) or eicosapen-
tanoic acid (EPA) aggravates or reduces, respectively, the
edema in animal models (rabbits) with respiratory failure
in sepsis [44]. Administration of AA is accompanied by a
higher release of leukotrienes and TXA2, whereas with the
administration of EPA LTB4 formation is blocked and
there are increases in n-5 series and TXA3 [43-48]. The
FO-rich lipid emulsions prob a b l yr e d u c et h ea d v e r s e
effects of the synthesis of mediators by the AA pathway,
such as pulmonary hypertension, pulmonary edema and
the accumulation of pulmonary neutrophils [43]. However,
little information is available on the possible modulation
with FO-enriched lipid emulsions in patients with ARDS.
In a recent trial with similar diet in a septic population, an
increase in EPA levels was demonstrated with a decrease
in cytokines and an improvement in gas exchange [21].
One of the limitations of our trial is the small popula-
tion size due to our decision to include ARDS patients
with low levels of multiorgan dysfunction. Because of
our trial design, with short periods of lipid emulsion
administration, we cannot draw conclusions regarding
either survival or quality of life. The baseline eicosanoid
differences were larger in arterial blood samples.
Conclusions
In our series of patients with ARDS, we found a favour-
able lipid mediator synthesis profile in patients treated
with an FO-enriched lipid emulsion, but not in patients
treated with LCT. This potentially significant finding
should be confirmed in clinical studies of patients
receiving parenteral nutrition with a lipid emulsion simi-
lar to the one used here. It is well known that these
mediators play a crucial role in this highly “inflamma-
tory” and severe process in patients with ARDS.
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